Apollomics (APLM) Total Non-Current Liabilities (2021 - 2025)

Apollomics (APLM) posted quarterly Total Non-Current Liabilities of $3.6 million for Q4 2025, up 328.26% year-on-year from $835000.0 in Q4 2024, and down 29.12% on a QoQ basis from $5.0 million in Q2 2025.

Apollomics (APLM) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends

Apollomics (APLM) has reported Total Non-Current Liabilities for 5 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 328.26% year-over-year to $3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.6 million (up 328.26% YoY) and the FY2025 annual result came in at $3.6 million, up 328.26% from the prior year.
  • Total Non-Current Liabilities eased to $3.6 million in Q4 2025 per APLM's latest filing, from $5.0 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for APLM reached as high as $512.2 million in Q4 2022 and fell as low as $597000.0 in Q4 2023.
  • A 5-year average of $106.0 million and a median of $2.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2023 — Total Non-Current Liabilities tumbled 99.88% — and 2025, when it surged 351.66%.
  • Year by year, Total Non-Current Liabilities stood at $322.7 million in 2021, then surged by 58.71% to $512.2 million in 2022, then slumped by 99.88% to $597000.0 in 2023, then soared by 39.87% to $835000.0 in 2024, then jumped by 328.26% to $3.6 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $3.6 million, $5.0 million, and $835000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Apollomics 2.66 Bn 2.66 Bn - 3.58 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 3.58 Mn
Jun 30, 2025 5.05 Mn
Dec 31, 2024 835,000.00
Jun 30, 2024 1.12 Mn
Dec 31, 2023 597,000.00
Jun 30, 2023 1.55 Mn
Dec 31, 2022 512.24 Mn
Dec 31, 2021 322.74 Mn